PHARMAQ FISHTEQ AS
Score · fiscal year 2024
74of 100
How to read this: the company is ahead of 92 % of small companies in the same sector in 2024. What does this mean?
Rank: 336 of 3,976 · Sjømat
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2024, not a verdict on the company. Based on profitability 85 and solidity 66 out of 100 among small companies in the same sector in 2024. Methodology
Against the sector
PHARMAQ FISHTEQ AS is 24 points above the median for small companies in the same sector in 2024.
Median score 50 among 3,476 companies.
Against small companies in the same sector in 2024: operating margin 21.6% (median 3.7%) and equity ratio 66.3% (median 35.6%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 64 MNOK | 1 MNOK |
| Operating margin | 21.6% | 3.7% |
| Profit margin | 21.0% | 0.8% |
| Return on assets | 33.6% | 1.2% |
| Equity ratio | 66.3% | 35.6% |
| Debt-to-equity | 0.51 | 0.96 |
| Current ratio | 2.10 | 1.52 |
| Revenue growth | 19.0% | −5.9% |
| Revenue per employee | 1.00 MNOK | 1.56 MNOK |
The median and “ahead of” refer to small companies in the same sector in 2024. The bar shows the share of companies the figure is ahead of.
With an index of 74, PHARMAQ FISHTEQ AS does better than 92% of small companies in the same sector (3,481 companies) in 2024.
Score 2023–2025
- PHARMAQ FISHTEQ AS
- Median: small companies in the same sector
What the numbers say
PHARMAQ FISHTEQ AS had an operating margin of 21.6% and an equity ratio of 66.3% in 2024, and ranks 336 of 3,976 in Sjømat.
From 2023 to 2024: the equity ratio rose from 49.9% to 66.3% and the operating margin rose from 17.4% to 21.6%.
This text is generated automatically from the 2024 accounts.
Three simple methods
The methods give between 29 MNOK and 111 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 105 MNOK |
| EV/EBIT | 8.0 | 111 MNOK |
| P/B | 1.0 | 29 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
No rules were triggered for this year.
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 7.5% of the debt in 2024. The policy rate averaged 4.50 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of −5.0%. Based on the 10 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 85 | weight 30% |
|---|---|---|
| Solidity | 66 | weight 25% |
| Liquidity | 58 | weight 15% |
| Growth | 73 | weight 15% |
| Consistency | 82 | weight 15% |
Durability: 68 (average over 2 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is PHARMAQ FISHTEQ AS?
The operating margin was 21.6% in 2024, against a median of 3.7% among small companies in the same sector. Return on assets was 33.6%.
How solid is PHARMAQ FISHTEQ AS?
The equity ratio was 66.3% in 2024 (median 35.6%). Debt-to-equity was 0.51 (median 0.96).
What is the liquidity of PHARMAQ FISHTEQ AS like?
The current ratio was 2.10 in 2024 (median 1.52).
How does PHARMAQ FISHTEQ AS compare in Sjømat?
PHARMAQ FISHTEQ AS ranks 336 of 3,976 in Sjømat for 2024. Among companies of the same size (small companies) it ranks 294 of 3,481. Revenue changed by 19.0% from the year before.
From the Central Coordinating Register
- Org. no.
- 975353346
- Legal form
- AS
- Sector
- Sjømat (03.300)
- Size tier
- small
- Employees
- 64 registered 10 September 2026
- Founded
- 5 September 1995 31 years in operation
- Share capital
- 0.08 MNOK
- Business address
- Havnevegen 6, 8700 NESNA
- Municipality
- Nesna rank 1–17 of 36 in KOSTRA group 15
- Latest accounts filed
- 2025
- Website
- www.vaksinering.com
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Nils Arne Grønlie
- Chair of the board
- Trine Astrid Vatle
- Board member
- Knut-Egil Løkling
- Board member
- Terje Tingbø
- Auditor
- KPMG AS
- Accountant
- ERNST & YOUNG COMPLIANCE SERVICES AS
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 28 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 61 | 74 | 69 | |
| Rank | 1,100 | 336 | 535 | |
| Operating margin | 17.4% | 21.6% | 15.5% | |
| Return on assets | 28.4% | 33.6% | 19.6% | |
| Equity ratio | 49.9% | 66.3% | 70.1% | |
| Current ratio | 1.21 | 2.10 | 2.52 | |
| Revenue growth | – | 19.0% | 14.4% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 53.9 MNOK | 64.2 MNOK | 73.4 MNOK |
| Operating profit | 9.4 MNOK | 13.9 MNOK | 11.4 MNOK |
| Profit before tax | 8.7 MNOK | 13.5 MNOK | 10.4 MNOK |
| Net profit | 6.7 MNOK | 10.5 MNOK | 8.1 MNOK |
| Financial expenses | 1.7 MNOK | 1.1 MNOK | – |
| Total assets | 36.8 MNOK | 43.5 MNOK | 52.7 MNOK |
| Current assets | 22.3 MNOK | 30.8 MNOK | 39.6 MNOK |
| Equity | 18.4 MNOK | 28.9 MNOK | 36.9 MNOK |
| Retained earnings | 6.7 MNOK | 17.3 MNOK | 25.3 MNOK |
| Total liabilities | 18.4 MNOK | 14.7 MNOK | 15.7 MNOK |
| Current liabilities | 18.4 MNOK | 14.7 MNOK | 15.7 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 28 October 2026, accounts id 6042769.
Further
Similar companies
- EMBLA KYSTFISKE AS index 74, rank 334 · compare
- CMJ HOLDING AS index 74, rank 335 · compare
- RØTTINGEN HAVFISKE AS index 74, rank 337 · compare
- KRIKAR AS index 74, rank 338 · compare
- RLS INVEST AS index 74, rank 339 · compare